Cbl-b-IN-29
Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research.
For research use only. We do not sell to patients.
- CAS No.: 3070411-10-5
- Formula: C30H34FN5O
- Molecular Weight:499.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Cbl-b-IN-29 (compound 20) has a low risk for CYP inhibition/induction and hERG inhabitation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CT26 tumor cells (3×105)-induced BALB/c mice (6-8 weeks)[1]
-
Dosage:30 mg/kg
-
Administration:p.o., once daily for 15 days
-
Result:Resulted in a robust anti-tumor efficacy with a tumor growth inhibition (TGI) of 76%.
Indicated a low risk for CYP inhibition/induction and herg inhibition.
Exhibited good animal tolerability, with no observed adverse 412 reactions. .
Chemical Information
-
CAS No. 3070411-10-5
-
Molecular Weight 499.62
-
Formula C30H34FN5O
-
SMILES
CN1C([C@]2(C[C@@H](C)C2)C3=CC(C4=CC5=C(C([C@@H](C)NC6CCCC6)=CC=C5F)NC4=O)=CC=C3)=NN=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)